$59.16
+1.35
(+2.34%)▲
0.9%
Downside
Day's Volatility :3.73%
Upside
2.86%
56.47%
Downside
52 Weeks Volatility :57.11%
Upside
1.47%
Period | Crinetics Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 22.48% | 1.4% | 0.0% |
6 Months | 24.13% | 3.8% | 0.0% |
1 Year | 100.41% | 15.3% | 0.0% |
3 Years | 112.73% | 11.4% | -27.4% |
Market Capitalization | 5.2B |
Book Value | $10.47 |
Earnings Per Share (EPS) | -3.76 |
Wall Street Target Price | 71.31 |
Profit Margin | 0.0% |
Operating Margin TTM | -20747.62% |
Return On Assets TTM | -28.27% |
Return On Equity TTM | -47.66% |
Revenue TTM | 1.4M |
Revenue Per Share TTM | 0.02 |
Quarterly Revenue Growth YOY | -59.599999999999994% |
Gross Profit TTM | -125.5M |
EBITDA | -276.2M |
Diluted Eps TTM | -3.76 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.69 |
EPS Estimate Next Year | -3.86 |
EPS Estimate Current Quarter | -0.86 |
EPS Estimate Next Quarter | -0.88 |
What analysts predicted
Upside of 20.54%
Sell
Neutral
Buy
Crinetics Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Crinetics Pharmaceuticals Inc | 14.3% | 24.13% | 100.41% | 112.73% | 209.09% |
Regeneron Pharmaceuticals, Inc. | -18.01% | -15.81% | -1.7% | 31.13% | 150.21% |
Biontech Se | -12.27% | 17.34% | 4.17% | -56.04% | 478.94% |
Alnylam Pharmaceuticals, Inc. | 2.34% | 76.9% | 60.41% | 45.24% | 198.24% |
Vertex Pharmaceuticals Incorporated | 10.04% | 20.33% | 30.51% | 156.8% | 152.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Crinetics Pharmaceuticals Inc | NA | NA | NA | -3.69 | -0.48 | -0.28 | NA | 10.47 |
Regeneron Pharmaceuticals, Inc. | 20.49 | 20.54 | 1.22 | 44.74 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -2.99 | -0.03 | -0.02 | NA | 85.17 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -1.87 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.27 | 0.19 | -0.03 | 0.12 | NA | 60.66 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Crinetics Pharmaceuticals Inc | Buy | $5.1B | 209.09% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $91.1B | 150.21% | 20.49 | 33.61% |
Biontech Se | Buy | $26.5B | 478.94% | 160.8 | -18.75% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.8B | 198.24% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $121.6B | 152.08% | 32.84 | -4.51% |
Insights on Crinetics Pharmaceuticals Inc
Revenue is down for the last 2 quarters, 640.0K → 399.0K (in $), with an average decrease of 37.7% per quarter
Netprofit is down for the last 8 quarters, -40.39M → -74.05M (in $), with an average decrease of 9.1% per quarter
BlackRock Inc
Driehaus Capital Management LLC
Wellington Management Company LLP
Vanguard Group Inc
T. Rowe Price Associates, Inc.
EcoR1 Capital, LLC
Crinetics Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read Moreneuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
Organization | Crinetics Pharmaceuticals Inc |
Employees | 290 |
CEO | Dr. R. Scott Struthers Ph.D. |
Industry | Health Technology |